ADVFN Logo
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

MRK Merck and Co Inc

104,0001
1,52 (1,48%)
02 Déc 2023 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Merck and Co Inc MRK NYSE Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
1,52 1,48% 104,0001 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
102,91 102,66 103,6761 103,46 102,48
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/11/202323:00BWFDA Grants Priority Review to Merck’s Application for..
29/11/202315:00BWAWS and Accenture Help Merck Use Cloud Technology to Reduce..
28/11/202322:51EDGAR2Form 8-K - Current report
28/11/202320:10DJNMerck Raises Quarterly Dividend 5.5% To 77 Cents
28/11/202319:17BWMerck Announces First-Quarter 2024 Dividend
28/11/202312:45BWMerck’s V116, an Investigational, 21-valent Pneumococcal..
21/11/202312:45BWMerck to Acquire Caraway Therapeutics, Inc.
20/11/202312:45BWMerck to Participate in the 6th Annual Evercore ISI..
17/11/202313:45IHMARKETNEWSFriday’s Wall Street Highlights: Applied Materials,..
16/11/202323:40BWFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus..
13/11/202313:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/11/202314:35DJNMerck Gets CHMP Backing for Keytruda in Biliary Tract Cancer
10/11/202313:40BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
09/11/202323:05EDGAR2Form 144 - Report of proposed sale of securities
09/11/202315:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202322:38EDGAR2Form 144 - Report of proposed sale of securities
08/11/202312:45BWMerck to Participate in the Jefferies London Healthcare..
03/11/202321:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202320:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202311:50BWMerck to Participate in the UBS BioPharma Conference
01/11/202311:45BWFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus..
01/11/202311:30BWKEYTRUDA® (pembrolizumab) Significantly Improved Overall..
31/10/202316:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/10/202313:45IHNWCan Diabetes, Weight-Loss Drugs Get Even Better?
26/10/202314:30DJFRMerck a vu son bénéfice net augmenter au T3, grâce à un bond..
26/10/202314:05DJNMerck 3Q Profit Rose as Sales of Breast Cancer Treatment..
26/10/202313:08IHMARKETNEWSThursday’s Wall Street Highlights: Ford, Morgan Stanley,..
26/10/202312:38EDGAR2Form 8-K - Current report
26/10/202312:30BWMerck Announces Third-Quarter 2023 Financial Results
25/10/202313:30PRNCAKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) is..
22/10/202316:30BWKEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab..
21/10/202314:45BWMerck’s WELIREG® (belzutifan) Significantly Improved..
20/10/202320:37DJNTrending: Merck, Daiichi Sankyo Sign Development,..
20/10/202316:00BWMerck’s KEYTRUDA® (pembrolizumab) Plus Concurrent..
20/10/202314:02BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed..
20/10/202314:01BWKEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy..
20/10/202314:00BWKEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery..
20/10/202313:22IHMARKETNEWSFriday’s Wall Street Highlights: SolarEdge, Intuitive..
20/10/202309:05DJFRMerck et Daiichi Sankyo s'allient pour développer et..
20/10/202302:30DJNMerck, Daiichi Sankyo Ink Commercialization Deal for Up to..
20/10/202301:30BWDaiichi Sankyo and Merck Announce Global Development and..
17/10/202312:45BWMerck Receives Positive EU CHMP Opinion for PREVYMIS® for..
17/10/202301:55DJNMerck Gets FDA Approval for Resectable Lung Cancer Treatment..
17/10/202301:00BWFDA Approves KEYTRUDA® (pembrolizumab) for Treatment of..
16/10/202312:45BWEuropean Commission Approves KEYTRUDA® (pembrolizumab) as..
13/10/202313:45BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
10/10/202313:17DJNMerck: Phase 3 Keytruda Study Hits Second Goal in Non-Small..
10/10/202312:45BWMerck Highlights Innovative Oncology Portfolio and Pipeline..
10/10/202312:30BWMerck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary..
05/10/202313:47DJNMerck Keytruda Study Hits Key Goal in Advanced Bladder..

Dernières Valeurs Consultées

Delayed Upgrade Clock

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Support: support@advfn.fr